In addition, we have found that hMP-RM-1, a humanized version of the anti-erbB3 Ab MP-RM-1 [43], exhibited similar in vitro activity to specifically downregulate Survivin in erbB2-overexpressing breast cancer cells (data not shown). This evidence concerns the gene ERBB2 and breast carcinoma.